Sustained clinical safety and efficacy of a biodegradable-polymer coated sirolimus-eluting stent in "real-world" practice: Three-year outcomes of the CREATE (multi-center registry of EXCEL biodegradable polymer drug eluting stents) study

Catheterization and Cardiovascular Interventions

Volumn 79, Issue 2, 2012, Pages 211-216

  Han, Yaling ^a   Jing, Quanmin ^a   Li, Yi ^a   Yang, Lixia ^b   Liu, Huiliang ^c   Shang, Xiaoming ^d   Jiang, Tiemin ^e   Li, Zhanquan ^f   Zhang, Hua ^g   Yan, Gaoliang ^a  

^a Shenyang Northern Hospital   (China)

^b KUNMING GENERAL HOSPITAL   (China)

^c GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^d Tangshan Gongren Hospital   (China)

^e MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^f People s Hospital of Liaoning Province   (China)

^g Tumor Hospital   (China)

Author keywords

biodegradable polymer; drug eluting stent; PCI; percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; POLYMER; RAPAMYCIN;

ADULT; ARTICLE; BIODEGRADABLE IMPLANT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DISEASE FREE SURVIVAL; DRUG ELUTING STENT; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; SAFETY; STENT THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84856302334     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.23113     Document Type: Article

References (28)

1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323. (Pubitemid 37186209)
2. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004; 109: 1942-1947. (Pubitemid 38544483)
3. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ,. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004; 364: 583-591. (Pubitemid 39094175)
4. Liistro F, Colombo A,. Late acute thrombosis after paclitaxel eluting stent implantation. Heart 2001; 86: 262-264. (Pubitemid 32800072)
5. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C,. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48: 2584-2591. (Pubitemid 44881238)
6. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519-1521. (Pubitemid 39410418)
7. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW,. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005; 45: 2088-2092. (Pubitemid 40814135)
8. Cosgrave J, Corbett SJ, Melzi G, Babic R, Biondi-Zoccai GG, et al. Late restenosis following sirolimus-eluting stent implantation. Am J Cardiol 2007; 100: 41-44. (Pubitemid 46961896)
9. Park DW, Hong MK, Mintz GS, Lee CW, Song JM, et al. Two-year follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitaxel-eluting stent implantation: Late "catch-up" phenomenon from ASPECT Study. J Am Coll Cardiol 2006; 48: 2432-2439. (Pubitemid 44881217)
10. Virmani R, Liistro F, Stankovic G, Di Mario C, Montorfano M, Farb A, Kolodgie FD, Colombo A,. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 2002; 106: 2649-2651. (Pubitemid 35364917)
11. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD,. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 2004; 109: 701-705. (Pubitemid 38222887)
12. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, et al. Hypersensitivity cases associated with drug-eluting coronary stents: A review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006; 47: 175-181. (Pubitemid 43005183)
13. Sousa JE, Costa MA, Farb A, Abizaid A, Sousa A, et al. Images in cardiovascular medicine. Vascular healing 4 years after the implantation of sirolimus-eluting stent in humans: A histopathological examination. Circulation 2004; 110: e5-e6.
14. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R,. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007; 27: 1500-1510. (Pubitemid 46986103)
15. Buszman P, Trznadel S, Milewski K, Rzezniczak J, Przewlocki T, et al. Novel paclitaxel-eluting, biodegradable polymer coated stent in the treatment of de novo coronary lesions: A prospective multicenter registry. Catheter Cardiovasc Interv 2008; 71: 51-57. (Pubitemid 351158346)
16. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): A randomised non-inferiority trial. Lancet 2008; 372: 1163-1173.
17. Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, et al. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: Primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. J Am Coll Cardiol 2008; 51: 1543-1552. (Pubitemid 351512313)
18. Han Y, Jing Q, Chen X, Wang S, Ma Y, et al. Long-term clinical, angiographic, and intravascular ultrasound outcomes of biodegradable polymer-coated sirolimus-eluting stents. Catheter Cardiovasc Interv 2008; 72: 177-183.
19. Han Y, Jing Q, Xu B, Yang L, Liu H, et al. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. JACC Cardiovasc Interv 2009; 2: 303-309.
20. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-2351. (Pubitemid 46685903)
21. Caixeta A, Leon MB, Lansky AJ, Nikolsky E, Aoki J, et al. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. J Am Coll Cardiol 2009; 54: 894-902.
22. Silber S, Colombo A, Banning AP, Hauptmann K, Drzewiecki J, Grube E, Dudek D, Baim DS,. Final 5-year results of the TAXUS II trial: A randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions. Circulation 2009; 120: 1498-1504.
23. Byrne RA, Iijima R, Mehilli J, Pinieck S, Bruskina O, Schomig A, Kastrati A,. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv 2009; 2: 291-299.
24. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008. (Pubitemid 46376800)
25. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P,. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association. American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007; 49: 734-739. (Pubitemid 46210116)
26. Schulz S, Schuster T, Mehilli J, Byrne RA, Ellert J, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J 2009; 30: 2714-2721.
27. Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362: 1374-1382.
28. Serruys PW,. LEADERS: Three-Year Follow-up from a Prospective Randomized Trial of Biolimus A9-Eluting Stents and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease. Presented at Transcatheter Cardiovascular Therapeutics, 22nd September, 2010; Washington DC, USA.